Free Trial

Envista (NVST) Projected to Post Quarterly Earnings on Wednesday

Envista logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Envista will report Q1 2026 results after the close on Wednesday, May 6, 2026; analysts expect $0.31 EPS and $677.95M in revenue, and the company set FY2026 guidance at $1.35–$1.45 EPS.
  • In the prior quarter (reported Feb. 5) Envista beat estimates with $0.38 EPS versus $0.32 expected and revenue rose 15% year‑over‑year; analysts project roughly $1.00 EPS for the current fiscal year and $2.00 for the next.
  • Shares trade near $26.28 with a $4.28B market cap, a P/E of about 93.7 and a 52‑week range of $15.49–$30.42; Wall Street’s consensus rating is a Hold with a $28.25 target (six Buys vs nine Holds).
  • Interested in Envista? Here are five stocks we like better.

Envista (NYSE:NVST - Get Free Report) is expected to announce its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.31 per share and revenue of $677.9480 million for the quarter. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 5:00 PM ET.

Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.38 EPS for the quarter, beating analysts' consensus estimates of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.Envista's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.24 earnings per share. On average, analysts expect Envista to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Envista Price Performance

Shares of Envista stock traded down $0.21 on Wednesday, reaching $26.28. The company's stock had a trading volume of 444,115 shares, compared to its average volume of 2,707,117. The company has a market capitalization of $4.28 billion, a P/E ratio of 93.66, a PEG ratio of 1.83 and a beta of 0.98. Envista has a 52-week low of $15.49 and a 52-week high of $30.42. The stock has a 50-day moving average price of $26.83 and a 200-day moving average price of $23.84. The company has a quick ratio of 2.04, a current ratio of 2.38 and a debt-to-equity ratio of 0.47.

Wall Street Analyst Weigh In

Several analysts recently commented on NVST shares. Leerink Partners set a $35.00 price target on Envista and gave the stock an "outperform" rating in a research report on Friday, February 6th. Wall Street Zen upgraded Envista from a "buy" rating to a "strong-buy" rating in a research report on Monday, January 26th. Robert W. Baird set a $30.00 price target on Envista in a research report on Friday, February 6th. Stifel Nicolaus set a $31.00 price target on Envista in a research report on Friday, February 6th. Finally, Piper Sandler reiterated a "neutral" rating and set a $25.00 price target (up from $21.00) on shares of Envista in a research report on Friday, February 6th. Six equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Envista has a consensus rating of "Hold" and a consensus target price of $28.25.

Read Our Latest Analysis on Envista

Insider Transactions at Envista

In other Envista news, SVP Mischa Reis sold 9,675 shares of the company's stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total value of $290,250.00. Following the completion of the sale, the senior vice president directly owned 32,382 shares in the company, valued at $971,460. This represents a 23.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.99% of the stock is currently owned by insiders.

Institutional Trading of Envista

Several large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP grew its holdings in Envista by 0.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 9,628,460 shares of the company's stock valued at $209,036,000 after buying an additional 90,586 shares in the last quarter. Alliancebernstein L.P. grew its holdings in Envista by 34.0% in the 2nd quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company's stock valued at $119,164,000 after buying an additional 1,547,656 shares in the last quarter. Millennium Management LLC grew its holdings in Envista by 1,442.7% in the 4th quarter. Millennium Management LLC now owns 2,420,615 shares of the company's stock valued at $52,552,000 after buying an additional 2,263,712 shares in the last quarter. AQR Capital Management LLC grew its holdings in Envista by 72.3% in the 4th quarter. AQR Capital Management LLC now owns 2,356,968 shares of the company's stock valued at $51,170,000 after buying an additional 988,714 shares in the last quarter. Finally, Deerfield Management Company L.P. grew its holdings in Envista by 3.5% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,294,036 shares of the company's stock valued at $46,730,000 after buying an additional 78,191 shares in the last quarter.

About Envista

(Get Free Report)

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company's offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista's product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.

Featured Articles

Earnings History for Envista (NYSE:NVST)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Envista Right Now?

Before you consider Envista, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.

While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines